My point was it will at least give them a life-line" by selling all their IP, and use those funds as start-up capital with the focus solely on IMMU using that $17M for R&D with way less staff costs. Their MC is currently that of a start-up bio-tech stock anyway so this will let them "survive" and go through getting their HSV commercialize, like they did for ADAPT but without requiring to do the heavy dilution as they have the funding for HSV (if what I read is correct), IMO.
Ann: Preliminary Final Report for period to 31 December 2018, page-43
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.49 |
Change
0.490(4.08%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $12.11 | $12.49 | $11.50 | $155.8K | 13.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 175 | $11.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.49 | 77 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |